NESS-040C5
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C27H33N3OS |
Molar mass | 447.64g·mol−1 |
3D model (JSmol) | |
|
NESS-040C5is a potentcannabinoidagonistwhich was developed for the treatment ofglaucoma.[1]It has reasonable selectivity for theCB2receptor subtype, having a CB2affinity of 0.4nM, and 25x selectivity over the relatedCB1receptor.[2]
See also
[edit]References
[edit]- ^Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
- ^Hanus LO, Mechoulam R (2010). "Novel natural and synthetic ligands of the endocannabinoid system".Current Medicinal Chemistry.17(14): 1341–59.doi:10.2174/092986710790980096.PMID20166928.
![]() | Thiscannabinoidrelated article is astub.You can help Wikipedia byexpanding it. |
Hidden categories: